Asset profile
aldesleukin · Proleukin
Other
Approvedregulatory verdict
Evidence outlook
Approved: Renal Cell Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Multiple Sclerosis · Phase 1Rheumatoid Arthritis
Featured evidence outside covered markets:NCT00018941 · Kidney Cancer · Phase 3 · completed · ungradedNCT00026312 · Localized Resectable Neuroblastoma · Phase 3 · completed · ungraded
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
103 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 103 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Aldesleukin (Proleukin): this drug | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | ||
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | ||
| CT-P13 (Inflectra / Remsima) | Approved | Monoclonal antibody | TNF-alpha | ||
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) |
…and 88 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(26 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
Phase 2Malignant NeoplasmActive not recruiting
Est. primary completion 2026-11-02 · NCT01697527 · CT.gov ↗
What to watch
2027 (11)
January 2027 (3)
Phase 1Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive DiseaseActive not recruiting
Est. primary completion 2027-01 · NCT03546426 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck NeoplasmsActive not recruiting
Est. primary completion 2027-01-01 · NCT06237881 · CT.gov ↗
What to watch
Phase 1Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8Recruiting
Est. primary completion 2027-01-07 · NCT05493566 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1/2Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma, Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT05267626 · CT.gov ↗
What to watch
April 2027 (4)
Phase 1/2Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally AdvancedRecruiting
Est. primary completion 2027-04 · NCT07255664 · CT.gov ↗
What to watch
Phase 2Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer, VaccinationRecruiting
Est. primary completion 2027-04 · NCT04166006 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer, Surgery, Metastasis, ImmunosuppressionNot yet recruiting
Est. primary completion 2027-04-01 · NCT05810792 · CT.gov ↗
What to watch
Phase 1Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma …Active not recruiting
Est. primary completion 2027-04-24 · NCT05802056 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1/2Crohn DiseaseRecruiting
Est. primary completion 2027-06-30 · NCT04263831 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1/2Uveal Melanoma, Metastatic Uveal Melanoma, Metastatic Uveal Melanoma in the LiverRecruiting
Est. primary completion 2027-09 · NCT07063875 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Solid Tumor, AdultActive not recruiting
Est. primary completion 2027-11 · NCT04643574 · CT.gov ↗
What to watch
2028 (5)
April 2028 (1)
Phase 1/2Triple Negative Breast CancerNot yet recruiting
Est. primary completion 2028-04 · NCT05821686 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Alzheimer DiseaseActive not recruiting
Est. primary completion 2028-06-08 · NCT05468073 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric, Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09-15 · NCT06158828 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1Unresectable or Metastatic MelanomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07700121 · CT.gov ↗
What to watch
November 2028 (1)
Early phase / not applicableCoronary Artery Disease, Myocardial Infarction (MI), CABGRecruiting
Est. primary completion 2028-11-01 · NCT07610538 · CT.gov ↗
What to watch
2029 (4)
April 2029 (2)
Phase 1Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma …Active not recruiting
Est. primary completion 2029-04-30 · NCT01590069 · CT.gov ↗
What to watch
Phase 1Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms …Recruiting
Est. primary completion 2029-04-30 · NCT06904066 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1Graft Versus Host Disease (cGvHD)Recruiting
Est. primary completion 2029-05-01 · NCT06991361 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Alzheimer Dementia (AD)Recruiting
Est. primary completion 2029-06 · NCT07651319 · CT.gov ↗
What to watch
2030 (1)
March 2030 (1)
Phase 1/2Relapsed Adult AML, Refractory AML, Acute Myelogenous LeukemiaRecruiting
Est. primary completion 2030-03-01 · NCT07591649 · CT.gov ↗
What to watch
2031 (3)
March 2031 (1)
Phase 1/2Relapsed or Refractory Multiple MyelomaRecruiting
Est. primary completion 2031-03-06 · NCT07681596 · CT.gov ↗
What to watch
September 2031 (1)
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2031-09-01 · NCT05155033 · CT.gov ↗
What to watch
December 2031 (1)
Phase 1/2Ovarian Cancer, Advanced Malignant Solid TumorNot yet recruiting
Est. primary completion 2031-12-10 · NCT07389239 · CT.gov ↗
What to watch
2039 (1)
August 2039 (1)
Phase 1/2Select Advanced Solid TumorsRecruiting
Est. primary completion 2039-08-01 · NCT06598371 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.